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METHODS: Five renal centres were investigated. All resources
used during the process of dialysis treatment were identiﬁed
during semi-structured interviews; published costs were applied.
Overhead costs were apportioned using standard cost account-
ing. RESULTS: Annual costs of HD in main units ranged from
£33,516 to £45,029 (£30,508 to £46,459 in satellite units). A
key differential factor between the units was the overhead costs.
HD costs without overheads ranged from £30,055 to £35,138
(£23,110 to £35,227 in satellite units). Annual costs of PD were
£14,859 to £17,022 and £22,196 to £24,358 for CAPD and
APD, respectively. The key differential cost drivers between HD
and PD other than overheads were disposables (averaging
£10,117 for HD, £9,349 for CAPD and £16,223 for APD),
nursing (£9,921 for HD; £2,775 for PD), anaemia therapy
(£7,005 for HD; £2,410 for PD) and transport (£2,352 for HD;
£130 for PD). CONCLUSION: Within individual renal centres,
the costs of delivering APD range from 32% to 50% lower than
HD and for CAPD costs are from 53% to 66% lower than HD.
Increased use of PD could result in more efﬁcient use of resources
from the perspective of purchasers and the government. More-
over, this type of treatment aligns with the UK government’s
strategy of patient choice and self-care in a home environment.
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OBJECTIVES: To quantify and compare staff time related to
anaemia management with currently available ESA drugs in hae-
modialysis centres and to model the potential efﬁciency gains
with adoption of once-monthly C.E.R.A. (continuous erythro-
poietin receptor activator) injections. METHODS: A multicen-
tre, prospective, activity-based costing study was undertaken in
17 dialysis centres across 3 countries. Tasks were grouped into
observable tasks (ESA preparation and administration) and
quantiﬁed through time and motion observations. Time for non-
observable tasks (e.g. ESA inventory/ordering, blood sampling,
physician review) was estimated through staff interviews. Time
was translated into cost using estimates of national wages for
personnel. ESA acquisition costs were excluded. RESULTS:
Average observed time and cost per ESA administration was 1.67
minutes (€0.53) in Germany, 2.67 minutes (€1.55) in the UK and
2.35 minutes (€1.92) in the US. Time per patient per year varies
primarily due to the different mix of products and their frequency
of administrations. The weighted average number of ESA injec-
tions per patient per week (year) was 1.8 (94) across the German
centres, 1.6 (83) in the UK and 3 (155) in the US centres. Time for
non observable tasks account for 40 to 60% of the total time
related to anaemia activities. Modelling estimated that with
once-monthly C.E.R.A time for the observed activities would be
28 to 32 minutes per patient per year (>80% reduction). Addi-
tional savings could be generated related to non-observable
tasks. The order of magnitude of these savings may vary ac-
cording to the organization of the centres. CONCLUSIONS:
Anaemia management with ESAs appears fairly standardized
across dialysis centres and countries and accounts for a signiﬁ-
cant amount of staff time. With 12 injections of C.E.R.A. per
patient per year, substantial time savings could be achieved
enabling centres to focus on other aspects of patient care.
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OBJECTIVES: Hyperphosphatemia is associated with increased
mortality and morbidity for patients with chronic kidney disease
who receive dialysis. Treatments for hyperphosphatemia include
calcium- and other metal-based binders. However, metal-based
binders are associated with increased calciﬁcation, which is likely
to results in greater rates of complications and reduced survival.
This analysis compares the use of sevelamer, a non-metal-based
phosphate binder against calcium binders. The objective was to
estimate the costs and health outcomes associated with sevelamer
for treatment of hyperphosphatemia compared with calcium-
based binders in patients new to dialysis over ﬁve years, from the
perspective of the National Health Service in the UK. The model
was also adapted to three other European countries: Finland,
Poland and Germany. METHODS: A ﬁve-year deterministic
decision analysis model was designed in order to estimate and
compare the costs and outcomes of treatment with sevelamer
versus calcium acetate. The model used Markov techniques to
predict the monthly changes in health status (including inpatient
stay and survival). Mortality rates and hospitalisation rates were
drawn from published sources and patients using sevelamer had
a 79% risk reduction of hospitalizations for the ﬁrst 18 months
of the model. Costs were limited to those incurred by the health
care provider, and were drawn from national databases.
RESULTS: The total ﬁve-year discounted treatment cost for
patients treated with sevelamer is 24,216 compared to
17,985 for calcium acetate. Patients receiving sevelamer can be
expected to experience 2.70 quality-adjusted life years (QALYs)
compared to 2.46 for those treated with calcium acetate. The
incremental cost-effectiveness ratio (ICER) for sevelamer was,
therefore, 25,916 per QALY. CONCLUSION: Sevelamer pro-
vides unique therapeutic beneﬁts including a signiﬁcant relative
risk reduction in mortality and morbidity. As demonstrated in
this economic evaluation, the reduction in mortality and mor-
bidity translates into a substantial QALY gain with a modest
investment of additional economic resources.
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OBJECTIVES: The worldwide incidence of kidney failure con-
tinues to rise and treatment is costly; therefore, the burden of
illness, including the health care resources allocated to its treat-
ment, is growing. Given that the number of end-stage renal
disease (ESRD) patients is increasing and the majority is on some
form of dialysis, the number of dialysis patients is expected to
increase as well. The purpose of this assessment was to review
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published economic evaluations of dialysis treatment modalities,
including hemodialysis (HD) and peritoneal dialysis (PD).
METHODS: We conducted a systematic literature review of
original research articles comparing PD and HD (or their
subtypes) in both PubMed and EMBASE for the years 1996 to
2006. Articles were included if they 1) came under the major
subject headings of “renal replacement therapy/economics,” or
“dialysis/economics,” or “renal dialysis/economics,” or “hemo-
dialysis units, hospital/economics,” or “kidney failure, chronic/
economics”, and 2) contained the term “peritoneal dialysis” and
either the term “hemodialysis” or “haemodialysis”. Pre-deﬁned
exclusion criteria were also applied. RESULTS: Twenty-ﬁve
articles were included in the formal literature review. The major-
ity of articles were cost evaluations, rather than full economic
evaluations of both costs and outcomes. The results show that, in
developed nations, HD is generally more expensive than PD to
the payer. Research is more limited in developing and emerging
countries. Due to inexpensive labor and high imported equip-
ment and solution costs, PD is perceived to be more expensive
than HD; however, the costs of dialysis differ by region and
additional research is needed in the developing world. CON-
CLUSION: HD is a more expensive dialysis modality in devel-
oped regions of the world. Research in the developing world is
too limited to draw deﬁnitive conclusions.
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OBJECTIVES: Vesicoureteral reﬂux (VUR) occurs in approxi-
mately 1% of infants and children and is associated with recur-
rent urinary tract infections (UTIs). Guidelines in the treatment
of VUR target reducing the number of UTIs in patients with
VUR. Treatment strategies include antibiotic prophylaxis, which
is the current ﬁrst-line treatment, as well as endoscopic injection
and surgery. The objective of this study is to examine the use of
endoscopic injection with dextranomer/hyaluronic acid (Dx/HA)
as a curative option and as an alternative to antibiotic prophy-
laxis as it is gaining in popularity in the treatment of VUR.
METHODS: The nationally representative PharMetrics Inte-
grated Medical and Pharmaceutical database was used to
conduct this retrospective analysis. Patients <11 years of age who
were continuously eligible with an International Classiﬁcation of
Diseases (ICD)-9-CM for VUR were identiﬁed. Resource utiliza-
tion and outcome measures were evaluated over a 6-month pre-
and 12-month post-index period. As randomization is not pos-
sible in a retrospective database analysis, patients were matched
3:1, antibiotic prophylaxis to Dx/HA, by age, gender, urinary
tract infections (UTIs) prior to index date, and diagnosing
physician specialty. The primary outcome assessed was UTIs.
RESULTS: Of the patients, 114 received a prescription for anti-
biotic prophylaxis and 38 underwent endoscopic injection with
Dx/HA between January 2000 and December 2004. The average
number of UTIs per year was 0.28 in the antibiotics cohort and
0.08 in the Dx/HA cohort, respectively. The incidence rate ratio
(IRR) of 4.826 (P = 0.029) revealed that the average number of
UTIs was 3.83 times greater for patients receiving antibiotic
prophylaxis compared with patients who underwent endoscopic
injection. CONCLUSION: Treatment with endoscopic injection
with Dx/HA resulted in signiﬁcantly fewer UTIs compared with
children receiving antibiotic prophylaxis, supporting a role for
Dx/HA as a ﬁrst-line treatment option for patients with VUR.
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OBJECTIVES: Around 1990 there was a social change in the
former socialist countries of Central and Eastern Europe. The
former dominance of the state has changed and many private
health care providers entered into the Hungarian health care
market. The aim of this study is to analyse how the market share
of private dialysis centres has changed. METHODS: Data were
derived from the nationwide database of the Hungarian National
Health Insurance Fund Administration (OEP), the only health
care ﬁnancing agency in Hungary. We analysed the period
between 1995 and 2005. Dialysis centres were classiﬁed into 3
major groups according to their ownership: private, central gov-
ernment (mainly at universities) and local authorities (mainly at
county level hospitals). All the Hungarian dialysis centres are
included into the study regardless of their ownership. RESULTS:
The market share of different type of providers in 1995 from
health insurance expenditures was the following: private provid-
ers 46.3%, central government 20.6% and local authorities
33.1%, which means that public ownership (20.6 + 33.1 = 53.7)
dominated the dialysis care. The market share of providers sig-
niﬁcantly changed for 2005: private providers 89.8%, central
government 5.3% and local authorities 4.9%. Between 1995–
2005 private providers doubled their market share, while dialysis
centres owned by the central government or local authorities lost
15.3 and 28.2 percent point respectively. CONCLUSION: The
ownership structure of dialysis centres dramatically changed in
Hungary after the social and political changes in the early 1990s.
The previous dominance of the state has disappeared, and most
of the dialysis care is provided by private for-proﬁt dialysis
centres.
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OBJECTIVES: To evaluate treatment outcomes, medical care
and resource consumption of patients with neurogenic detrusor
overactivity (NDO) before and after botulinum toxin A (BTA)
therapy in Germany. METHODS: In a multi-center, cross-
sectional, retrospective cohort study, information such as demo-
graphic characteristics, number of BTA therapies, urodynamic
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